Published Aug 5, 2026, 7:01 PM ET · Updated 3 months ago · 1 source

Revolution Medicines updates 2026 GAAP operating expenses to $2.1B-$2.2B while preparing potential daraxonrasib launch

Seeking Alpha

Original Report